The Covid vaccine clearly does not work against Omicron, says the head of the EMA

Preliminary evidence points to a “significant” decline in the effectiveness of the modern Covid-19 vaccine against the Omicron genus coronavirus, according to a European Medicines Agency official, who said it would take time to adapt to a multimodal vaccine. will need.

Less research shows a decrease in the number of antibodies while two anti-Omicron vaccines for mRNA vaccine, as well as adenovirus vaccines such as Oxford / AstraZeneca and Johnson and Johnson.

“What is coming is… Not sure at all, there are very few statistics, [but] it is clear that employment is declining, ”Emer Cooke, chief executive of the European Medicines Agency, told the Financial Times. “How much, we do not know.”

But preliminary evidence also suggests that a third dose of mRNA vaccine may slightly reverse antibodies. On Monday, Modern became a recent vaccine maker to explain the findings of the study by saying that the third dose causes the antibodies to change. Scientists say they believe a complete vaccine can still protect against serious infections.

“Kaya [the drop in effectiveness] they can be paid for and promote what we do not know, so for us it is a lot, “Cooke said.”

Cooke also said AstraZeneca did not register for the shot to be used as a boost in the bloc. The company said it had donated a lot to be seen as a facilitator, and that it continued to work with the EMA.

He encouraged ordinary people as well to take part in solving this great task: “One of the things you and other people can do is keep up the pressure … there are going to be some difficult decisions for government”.

“This is what we need to do as a message now, and let science happen,” he said. “But if we stop vaccinating and promoting it, we will lose it for a few months.”

The idea that Omicron vaccines are needed will be developed “when there is sufficient scientific evidence that modern vaccines do not work”, he said, adding that Omicron was a “high risk” that should be tested by various experts. groups around the world.

Any idea, he said, was not about the EMA, but it was a global science to come to an agreement.

Many vaccinators have announced plans to launch a new Omicron vaccine trial.

As to whether a vaccine is needed, Cooke said the agency will ask more questions about its ability to make antibodies and production capabilities. But it is not yet clear whether the agency will request the training from people who are vaccinated or not and how much equipment the training will be, he said.

He also repeated the “properties” of various vaccines the need to deal with the risks of production and efficiency.

“We have to take care of the things that matter[of existing vaccines]and to seek new things, ”he said, to encourage“ healthy competition ”and to give the director the power to investigate whether others could do better in certain situations.

“[As a regulator] you know people want answers yesterday, ”he said. “You also want to give the right answer. And the right answer takes time. ”